05:54 AM EDT, 07/21/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) received a notice of allowance from the Israeli patent office for its patent application covering POLB 001, its preventative therapy for cancer immunotherapy-induced cytokine release syndrome. The clinical-stage biopharmaceutical company said Tuesday that the application is expected to proceed to formal grant in due course. The notice of allowance follows a regulatory decision to grant the patent application in Europe and formal patent grants in Australia and Canada.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.